Table 5 Comparison of mean methylation between normal and tumor samples for the 17 genes studied with respect to the BRCA2 -26 5'UTR polymorphism

TRAIL

26 ^a, 26 ^b, 2 ^c

48% ^a, 48% ^b, 4% ^c

0.655

0.696

14, 10, 3

52%, 37%, 11%

0.555

0.858

DR4

31, 21, 2

57%, 39%, 4%

0.033

0.070

16, 11, 0

59%, 41%, 0%

0.175

0.595

DR5

14, 37, 3

26%, 69%, 6%

0.001

0.006

11, 15, 1

41%, 56%, 4%

0.394

0.837

DCR1

18, 36, 0

33%, 67%, 0%

0.0001

0.001

11, 16, 0

41%, 59%, 0%

0.038

0.215

DCR2

12, 41, 1

22%, 76%, 2%

0.0000002

0.000003

4, 22, 1

15%, 81%, 4%

0.0008

0.014

CASP8

20, 32, 2

37%, 59%, 4%

0.006

0.026

11, 15, 1

41%, 56%, 4%

0.970

0.970

BCL2

29, 24, 1

54%, 44%, 2%

0.972

0.972

12, 15, 0

44%, 56%, 0%

0.914

1.036

FLIP

32, 19, 3

59%, 35%, 6%

0.009

0.026

13, 14, 0

48%, 52%, 0%

0.952

1.012

CYCS

25, 29, 0

46%, 54%, 0%

0.164

0.253

8, 19, 0

30%, 70%, 0%

0.139

0.591

ATM

30, 22, 2

56%, 41%, 4%

0.303

0.429

13, 12, 2

48%, 44%, 7%

0.443

0.837

TP53

18, 33, 3

33%, 61%, 6%

0.029

0.070

14, 12, 1

52%, 44%, 4%

0.334

0.811

BRCA1

19, 35, 0

35%, 65%, 0%

0.065

0.123

15, 12, 0

56%, 44%, 0%

0.648

0.918

BRCA2

15, 34, 5

28%, 63%, 9%

0.008

0.027

9, 14, 4

33%, 52%, 15%

0.273

0.774

CHEK2

23, 25, 6

43%, 46%, 11%

0.320

0.418

12, 14, 1

44%, 52%, 4%

0.829

1.084

TIP60

28, 21, 5

52%, 39%, 9%

0.466

0.528

13, 12, 2

48%, 44%, 7%

0.893

1.084

RNF8

28, 24, 2

52%, 44%, 4%

0.454

0.551

18, 9, 0

67%, 33%, 0%

0.025

0.213

H2AX

17, 34, 3

31%, 63%, 6%

0.152

0.258

13, 12, 2

48%, 44%, 7%

0.535

0.910